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Prophylactic muscle flaps in vascular surgery
John P. Fischer, MD,a Jonas A. Nelson, MD,a Michael N. Mirzabeigi, BS,a Grace J. Wang, MD,b
Paul J. Foley III, MD,b Liza C. Wu, MD,a Edward Y. Woo, MD,b and Suhail Kanchwala, MD,a
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Background: Vascular surgery-related groin complications can lead to catastrophic outcomes and pose a significant
healthcare burden. We have taken steps to reduce potential complications at the time of initial surgery by performing
prophylactic muscle flaps. The purpose of this study is to evaluate the efficacy and benefit of prophylactic flaps in high-risk
patients.
Methods: A retrospective cohort study was performed on patients undergoing open vascular surgery involving the femoral
vessels through a groin incision between 2005 and 2010. Patients receiving prophylactic muscle flaps at their initial
surgery were compared with those patients not receiving a flap (control).
Results: Sixty-eight prophylactic flaps in 53 patients were compared with 195 open vascular procedures without flaps in
178 patients. The most frequent indication was reoperative bypass surgery with prosthetic reconstruction (63%). The
prophylactic patient group exhibited significantly higher rates of comorbidities, including chronic obstructive pulmonary
disease (25.0% vs 12.6%; P  .018) and hyperlipidemia (80.9% vs 59.1%; P  .002). Patients receiving prophylactic flaps
had lower rates of overall complications (16.2% vs 50.3%; P < .001), infections (1.5% vs 38.5%; P < .001), seroma (0%
vs 7.2%; P  .023), and lymphocele (1.5% vs 15.4%; P  .002). Multivariate regression demonstrated that obesity (odds
ratio [OR], 2.1 [1.001-4.49]; P  .05), smoking (OR, 2.7 [1.37-5.16]; P  .004), reoperation (OR, 3.5 [1.41-8.63];
P  .007), and prosthetic graft reconstruction (OR, 2.0 [1.03-3.78]; P  .04) were associated with postoperative
complications. Additionally, in analyzing all groin complications in all patients, we found that patients who received a
prophylactic flap experienced significantly less groin wound complications (OR, 0.17; P < .001).
Conclusions: Complications following open groin surgery are common, lead to significant morbidity, and are very costly.
Performing prophylactic muscle flaps at the initial surgery to cover the femoral vessels and reduce dead space can
significantly reduce complications in select high-risk patients. Prophylactic flaps are safe, effective, and should be
considered in patients with multiple comorbidities undergoing high-risk groin surgery, such as reoperative prosthetic
bypass surgery. (J Vasc Surg 2012;55:1081-6.)
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procedures are associated with significant morbidity and
cost. Complex groin wounds are prone to myriad compli-
cations, including superficial cellulitis, lymphatic leak, deep
wound infection, graft sepsis, and even limb loss. These
complications have been reported to occur in between 10%
and 44% of infrainguinal procedures.1
Several patient characteristics (obesity, smoking his-
tory), past medical and surgical history (diabetes, prior
groin surgery), and physical examination findings (groin
wound drainage) have been shown to increase the risk of
surgical site infections.2,3,4 Consequently, patients who
develop superficial wound complications, particularly those
with surgical site infections have longer hospitalizations,
experience greater mortality, and accrue higher hospital
charges.5 Additionally, patients with surgical site infections
or groin complications, in the setting of graft or prosthetic
reconstruction, are at a five-fold greater risk for graft site
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doi:10.1016/j.jvs.2011.10.110nfection.6 These complications quickly translate into pa-
ient morbidity and healthcare costs. The added cost of
urgical site infections has been found to be between $3648
nd $6830 per patient.7
In an effort to avert the morbidity and cost of these
omplications, we advocate aggressive, early, and for the
igh-risk patient, prophylactic measures. This has allowed
or a more timely initiation of antibiotics, debridement, and
uscle flap coverage. Of these measures, muscular flap
overage often involves an interdisciplinary approach with
lastic surgery services. Muscle flaps for vascular coverage
ollowing open groin surgery have been described as effica-
ious, and often definitive, for the treatment of complex
roin wounds. These flaps have been demonstrated to
mprove the rate of vascular graft salvage with minimal
onor site morbidity.8-10 Early debridement and muscle
aps reduce graft sepsis and increase limb salvage in com-
licated groins and can also be efficacious in treating lym-
hatic complications.11-13 Overall, it has been shown that
arly use of muscle flaps improves wound healing and graft
alvage while reducing costs.14-16
As a large tertiary referral center, the University of
ennsylvania treats patients with a complex array of medical
omorbidities who are often referred for reoperative, high-
isk surgery. Our successful experience with muscle flaps in
he setting of groin complications has prompted an institu-
ionally directed trend toward aggressive, early deployment
f muscle flaps. Over the past several years, the vascular and
1081
a
h
s
s
t
v
u
a
p
t
c
m
c
fi
c
t
i
3
(
f
c
t
c
i
p
t
a
C
R
p
p
e
m
(
p
h
h
d
c
d
t
p
(
.
(
g
1
P
p
o
fl
r
JOURNAL OF VASCULAR SURGERY
April 20121082 Fischer et alplastic surgery divisions have worked in collaboration to
provide muscle flap coverage at the initial vascular surgery
procedure. These measures are reserved for select high-
risk patients, such as reoperative prosthetic bypass, for
whom we perform “prophylactic” muscle flaps. Similar
rationales have been employed in the setting of high-risk
knee17 and spine reconstructions.18 The purpose of this
study is to evaluate the use, efficacy, and safety of prophy-
lactic muscle flaps.
METHODS
A retrospective cohort study examined patients under-
going vascular surgery between 2005 and 2010. Institu-
tional Review Board approval was obtained for this retro-
spective study. Patients who underwent infrainguinal, open
vascular groin surgeries were included in the analysis.
Those undergoing concurrent open abdominal surgery,
those with prior muscle flaps, patients with active groin
infections from outside facilities, and those with incomplete
and/or unavailable early postoperative data, including pa-
tients who expired within 72 hours of surgery, were ex-
cluded (a total of 107 patients). A detailed review of
hospital and office records was performed and included the
following: operative reports, anesthesia records, outpatient
examinations, postoperative nursing records, and labora-
tory data. Additionally, financial data were obtained from
the Department of Finance at the Hospital of the Univer-
sity of Pennsylvania. These data were examined and com-
pared between study groups. Patients were placed into two
cohorts based on their surgical intervention: (1) those
undergoing prophylactic muscle flap at the time of the
initial vascular procedure or (2) those not undergoing a flap
at the initial procedure (control group). The initial muscle
flap procedure was performed prior to any wound compli-
cations.
Prophylactic muscle flaps were performed at the re-
quest of vascular surgery based on the perceived risk of
complications. These patients were frequently undergoing
high-risk procedures, usually reoperative surgery, and pos-
sessed known risk factors for complications. These consults
were either preoperative or intraoperative consultations
(95% of cases were preoperative consults). The plastic sur-
gery service accepted all consults and performed these flaps
upon request. An intraoperative decision algorithm was
used to determine flap type based upon several factors
including defect size, risk for infection, assessment of mus-
cle, and extent and location of vascular disease. The control
group used for comparison represented a historical control
of patients from the same time period that did not require a
prophylactic flap during the study period. The same vascu-
lar surgeons performed procedures in these patients but did
not elect to utilize prophylactic muscle flaps.
Prophylactic muscle flap patients were compared with
control patients with respect to comorbidities, operative
characteristics, and postoperative complications. Specific
variables examined included age, gender, chronic obstruc-
tive pulmonary disease (COPD), diabetes, obesity and
body mass index (BMI), ASA, stroke history, coronary grtery disease (CAD), peripheral arterial disease (PAD),
yperlipidemia (HL), chronic renal insufficiency (CRI),
teroid or immunosuppression use, smoking, prior groin
urgeries, use of prosthetic graft, and length of hospitaliza-
ion. We additionally performed a subgroup analysis of
ascular procedure type to determine whether flaps were
sed selectively and to assess the role of flaps in either
utogenous or prosthetic bypass procedures. Primary end-
oints of interest included the incidence of seroma, hema-
oma, wound breakdown, lymphocele, infection (superfi-
ial or deep infection), limb loss, and need for a secondary
uscle flap for groin salvage as a result of postoperative
omplications (at a subsequent surgical procedure). Super-
cial infection was defined as incisional cellulitis that oc-
urred within 30 days, only involved skin and subcutaneous
issue structures, and was documented as such. A deep
nfection was defined as an infection that occurred within
0 days, was related to a prior surgery, involved deep tissues
ie, muscle or fascia), and was documented as such.
Statistical analysis included 2 and Fisher’s exact tests
or categorical variables and theWilcoxon rank-sum test for
ontinuous variables. A univariate analysis was performed
o determine predictors of overall complications. Signifi-
ant variables determined in this univariate analysis were
ncluded in a multivariate logistic regression to determine
redictive factors for complications. All tests were two-
ailed, and statistical significance was defined as P .05. All
nalyses were performed using Stata IC 10.0 (StataCorp,
ollege Station, Tex).
ESULTS
General. Sixty-eight prophylactic muscle flaps in 53
atients were compared with 195 open femoral access
rocedures without prophylactic flaps in 178 patients. The
ntire study population (178 patients) had high rates of
edical comorbidities, with diabetes (38.4%), CAD
50.5%), and peripheral vascular disease (76.8%). The pro-
hylactic muscle flap cohort did of note have significantly
igher rates of COPD (25.0% vs 12.6%; P  .018) and
yperlipidemia (80.9% vs 59.1%; P  .002; Table I). This
iscrepancy may have introduced some unavoidable re-
ruitment bias to our study. However, no other significant
ifferences in medical comorbidities were noted between
he two cohorts.
With regard to surgical outcomes, patients receiving
rophylactic flaps had lower rates of overall complications
16.2% vs 50.3%; P .001), infections (1.5% vs 38.5%; P
001), seroma (0% vs 7.2%; P  .023), and lymphocele
1.5% vs 15.4%; P  .002; Table II). The prophylactic flap
roup also had lower rates of wound breakdown (8.8% vs
9.0%; P  .051).
Indications, procedure type, and flap selection.
rophylactic groin flpas (PGFs) were requested in the
reoperative setting in 95% of cases. The most commonly
bserved indication for utilization of a prophylactic muscle
ap was a reoperative groin surgery with prosthetic graft
econstruction (63%), followed by reoperative groin sur-
ery without a prosthetic graft (13%). In 10% of cases, the
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Volume 55, Number 4 Fischer et al 1083indication was a prosthetic reconstruction, and in 9%, the
reason was solely patient-related comorbidities (most often
obesity or smoking).
We evaluated vascular procedures performed for con-
trol and PGF groups and did not find differences in proce-
dure type (Table III). A total of 195 vascular procedureswere
performed in the control group: 54 endarterectomies, 127
bypasses, 12 pseudoaneurysm repairs, and two endovascular
aneurysm repair (EVAR) procedures. We did, however, ob-
serve a significant difference in rates of PGFs in a subgroup
analysis of bypass procedures. Specifically, we observed that
Table I. Comorbidities of patients undergoing open
groin and prophylactic flaps
Control Prophylactic P
Number 195 68
Age 63.4 63.7 .6
Gender
M 62.6% (124) 61.8% (42) .79
F 35.9% (71) 38.2% (26)
Chronic obstructive
pulmonary disease 12.6% (25) 25.0% (17) .018
Diabetes mellitus 38.4% (76) 45.6% (31) .3
Obese 25.1% (50) 36.8% (25) .25
Body mass index 26.9 26.1 .56
American Society of
Anesthesiologists
 3 11.1% (22) 13.2% (9) .67
Cerebrovascular
accident 11.1% (22) 7.4% (5) .38
Hypertension 77.3% (153) 83.8% (57) .34
Coronary artery disease 50.5% (100) 51.5% (35) .98
Peripheral artery disease 76.8% (152) 91.2% (62) .16
Hyperlipidemia 59.1% (117) 80.9% (55) .002
Smoking
Current 34.8% (69) 35.3% (24) .95
Table II. Comparison of complications between open
groin surgery patients and prophylactic flaps
Control Prophylactic P value
Number 195 68
Hospital stay 12.3 days 13.3 days .072
Any complication 50.3% (98) 16.2% (11) .001
Seroma 7.2% (14) 0.0% (0) .023
Lymphocele 15.4% (30) 1.5% (1) .002
Hematoma all 4.1% (8) 5.8% (4) .55
Hematoma 2/2 vasc 4.1% (8) 2.9% (2) 1.000
Hematoma 2/2 flap 2.9% (2)
Groin infection (any) 38.5% (75) 1.5% (1) .001
Superficial infection 32.8% (64) 0.0% (0) .001
Deep infection 13.8% (27) 1.5% (1.5) .002
Wound breakdown 19.0% (37) 8.8% (6) .051
Amputation 6.2% (12) 4.4% (3) .59
Hospital stay with
complication 14.2 d 13.3 d .86
Secondary muscle flap 22.6% (44) 1.5% (1) .0001
Flap type
Sartorius 70.5% (31) 62.3% (43) .22
Rectus femoris 27.3% (12) 30.4% (21)PGFs were performed at a higher rate in prosthetic bypasses .ompared with bypasses with autogenous vein (57.4% vs
.5%; P  .0001). Interestingly, in analyzing complication
ates in the high-risk prosthetic bypass group, there was a
ignificantly lower rate of complications when a PGFwas used
12.8% vs 20.7%; P .001).
Regarding the choice of muscle flap for prophylactic
rocedures, we most frequently used the sartorius muscle
ap (SMF; 62%) followed by the rectus femoris (RF) flap
31%). Flap type was chosen by the attending plastic sur-
eon based on intraoperative findings and defect character-
stics (Figs 1 and 2). The SMF was similarly used in 71% of
ontrol group patients in whom a secondary salvage proce-
ure was needed. We clinically observed a 100% flap viabil-
ty in the prophylactic group with no difference in rates of
ematoma between prophylactic and control group pa-
ients (2.9% vs 4.1%; P  1.0).
Secondary muscle flaps. There were 44 secondary
uscle flaps performed for groin salvage in the control
roup for postoperative complications compared with only
ne patient in the prophylactic group (22.6% vs 1.5%; P 
able III. Comparison of vascular procedure type
Control Prophylactic P value
umber 195 68
ndarterectomy 27.7% (54) 32.4% (22) .36
ndovascular aneurysm
repair 1.0% (2) 0.0% (0)
seudoaneurysm repair 6.2% (12) 7.4% (5)
ypass 65.1% (127) 58.8% (40)
Bypass no prosthetic 26.3% (52) 1.5% (1)
Bypass with prosthetic 26.3% (52) 44.1% (30)
Aortobifemoral 10.6% (21) 0.0% (0)
Axillofemoral 1.0% (2) 13.2% (9)
ther 0.0% (0) 1.5% (1)
Skin defect
ALT or 
SMF/RF with 
STSG
Prophylactic 
flap
Defect size
SMF RF
YesNo
Small Large
ig 1. Algorithm for use of muscle flaps in prophylactic groin.
LT, Antero-lateral thigh flap; RF, rectus femoris; SMF, sartorius
uscle flap; STSG, split-thickness skin graft.001). Examining patients who underwent either a prophy-
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April 20121084 Fischer et allactic or secondary muscle flap, we found an increase in
length of stay for secondary flap procedures (16.1 days vs
13.3 days; P  .13). Control group patients receiving a
secondary muscle flap for groin salvage had a significantly
longer hospital stay compared to control patients not re-
quiring secondary flaps (16.1 days vs 11.1 days; P .001).
Risk factor analysis. Univariate analysis of the control
cohort revealed several variables to be significantly different
with respect to complication rates. Patients who developed
postoperative complications had higher rates of COPD
(18.4% vs 6.3%; P  .006), obesity (31.1% vs 17.9%; P 
.015), ASA 3 (15.5% vs 6.3%; P .025), PAD (80.6% vs
72.6%; P  .022), smoking history (69.9% vs 49.5%; P 
.001), reoperative groin (29.1% vs 8.4%; P  .001), and
prosthetic graft reconstruction (50.5% vs 32.6%; P .001).
Multivariate regression demonstrated that obesity (odds
ratio [OR], 2.1 [1.001-4.49]; P .05), smoking (OR, 2.7
[1.37-5.16]; P .004), reoperation (OR, 3.5 [1.41-8.63];
P  .007), and prosthetic graft reconstruction (OR, 2.0
[1.03-3.78]; P  .04) were associated with postoperative
complications (Table IV). In a separatemultivariate analysis
of all patients (both control and prophylactic groups), we
Fig 2. Example of rectus femoris used for prophylactic groin
flap.found that prophylactic muscle flaps significantly reduce froin wound complications (OR, 0.17; P .001), whereas
besity significantly increased rates of complications (OR,
.4; P  .004).
Cost analysis. In analyzing complication-associated
osts, we determined that complications added significant
ospital days, operating room costs, antibiotic usage, and
verall costs (Table V). These costs are most dramatic in
atients who require a secondary flap. Although there is an
dded cost of approximately $2400 to perform a prophy-
actic muscle flap, this is less than the added cost of a groin
omplication or a secondary flap for salvage. Patients who
equire salvage muscle flaps for complications have an
dded direct cost of around $6000.
ISCUSSION
The purpose of this study was to evaluate the efficacy
nd benefit of prophylactic muscle flaps in high-risk groin
urgery patients. We present a large 5-year cohort study
valuating the use of prophylactic muscle flaps and demon-
trate that these flaps are highly effective in reducing
ound-related complications. Additionally, prophylactic
aps are safe and easily harvested through an open groin
ncision with minimal donor-site morbidity and are not
ssociated with increased complications. Prophylactic mus-
le flaps are a potentially cost-effective and safe way to
educe complications in high-risk groin surgery patients.
he authors acknowledge the retrospective nature of this
tudy and the limitations associated with this. Despite this,
he trends noted in this study are noteworthy and serve as
he preliminary data to embark on a larger scale, random-
zed controlled study. Several points, however, are deserv-
ng of further discussion.
Prophylactic flaps appear to reduce complications and
eed for secondary salvage flaps. We employ these flaps as a
afety net in patients perceived to be at high risk for groin
omplications. Vascular surgeons at our institution typi-
ally seek preoperative plastic surgery consultation in pa-
ients undergoing reoperative surgery with anticipated
rosthetic reconstruction. In cases of reoperative groin
urgery with prosthetic reconstruction and significant med-
cal comorbidities, we utilize muscle flaps for graft coverage
nd protection against wound breakdown.
Muscle flaps and staged wound debridement can help
alvage the complicated groin, but the benefit of prophylactic
uscle flaps at the initial vascular procedure has not yet been
efined.We commonly utilize the SMF,RF, or gracilismuscle
able IV. Specific risk factors for groin wound
omplications
isk factors OR P value
besity 2.1 (1.001-4.49) .05
moking 2.7 (1.37-5.16) .004
eoperation 3.5 (1.41-8.63) .007
rosthetic reconstruction 2.0 (1.03-3.78) .04
R, Odds ratio.or this procedure. Of these, the SMF has been most fre-
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Volume 55, Number 4 Fischer et al 1085quently utilized, as it has been proven to be efficacious in the
compromised groin wound.19-22 The SMF has been estab-
lished as an effective muscle flap to improve groin wound
healing, reduce hospital stay, and prevent reinfection in the
complicated groin wound.23 Although the SMF is the initial
flap of choice, in wounds with a significant volume of dead
space following a vascular intervention, we utilize the RF due
to its greater size (Fig 1). While use of the rectus femoris
necessitates harvest of a larger muscle, the literature suggests
little functional deficit after muscle harvest.24
However, the SMF does offer several advantages over
other muscle flaps for use in the groin. This is particularly
true in the prophylactic setting. The SMF is in close ana-
tomic proximity to the femoral vessels, facilitating easy
transfer and access through the same groin incision. It has a
robust and segmental proximal blood supply, creating a
reliable vascular pedicle with minimal donor morbidity.25
Patients with obesity, smoking history, history of prior
groin surgery, and diabetes are at increased risk for surgical
site infections and groin complications.2-4 These patients
will benefit most from muscle coverage in the prophylactic
setting. In our regression analysis, we similarly demonstrate
that obesity, smoking, reoperative surgery, and prosthetic
reconstruction increase groin complications. Based on data
from our study, patients with multiple comorbidities un-
dergoing prosthetic-based reconstruction or reoperative
surgery will be at greater risk for postoperative groin com-
plications. In these patients, prophylactic muscle flaps may
reduce complications and hospital days. Prophylactic flaps
appear to reduce complication rates, need for a secondary
flap, and length of hospital stay with minimal risk of flap-
related complications. Without controlling for other fac-
tors and looking at control and PGF groups, patients not
receiving a prophylactic flap and undergoing reoperative
surgery are at 3.5 times greater risk for wound-related
complications compared to the prophylactic muscle flap
cohort. Furthermore, in patients undergoing reoperation
with a prosthetic graft, the use of a prophylactic flap de-
creases the complication rate by seven-fold.
Prophylactic flaps likely exhibit their protective effects by
augmenting wound and deep tissue perfusion, reducing bac-
terial load, and obliterating dead space. Specifically, musculo-
cutaneous flaps have been shown in animal studies to reduce
bacterial inoculum, inhibit bacterial growth, and optimize
Table V. Comparison of complication-related costs
Uncomplicated
Number 97
Hospital days per patient 10.2
Hospital costs per patient $7211
Operating room costs per patient 0
Antibiotic costs per patient 0
Total cost per patient $7211
Added cost per patient NA
NA, Not available.collagen deposition.26,27 Prophylactic flaps may mitigate bac- terial colonization of groin beds through upregulated blood
ow via enhanced bacterial suppression in the first 24 hours of
urgery, thereby reducing infectious complications.28
There are, however, notable drawbacks to our study. As
major referral center, we care for patients who are trans-
erred from outside institutions because of disease severity,
edical comorbidities, and overall high-risk health status.
s a consequence, our patient population has many of the
redisposing comorbidities increasing the risk for compli-
ations. Early success with secondary muscle flaps for graft
alvage has prompted our utilization of these flaps in the
rophylactic setting. At the start of the study period, fewer
rophylactic flaps were performed, whereas now, nearly all
atients with significant comorbidities undergo prophylac-
ic muscle flap procedures. As a consultant service, plastic
urgeons at our institution elected to perform all flaps based
pon requests of vascular surgeons. There may have been
atients whomight have benefitted from a PGF but did not
eceive one. Further studies might be needed to devise an
lgorithm to better target this patient subset.
Throughout our study, the surgeons, methods, tech-
ology, and antibiotic management have remained rela-
ively constant. As a retrospective study, we attempted to
ontrol for as many factors as possible. Of note, the pro-
hylactic cohort exhibited higher rates of COPD and HL,
hich may have introduced a selection bias to our study.
pecifically, we might have expected these patients to de-
elop higher rates of complications based on their comor-
idities and, thus, elected to utilize prophylactic flaps in
hese patients. In doing this, we may have artificially re-
uced the complication rate in this cohort. However, these
ntrinsic recruitment biases are due to the retrospective
ature of data acquisition. Additionally, we may have intro-
uced further recruitment and selection bias by excluding
atients who failed to meet inclusion criteria. These pa-
ients had concurrent open abdominal surgery, prior mus-
le flaps, active groin infections from outside facilities, or
ncomplete and/or unavailable early postoperative data.
We advocate the use of SMFs in high-risk groin surgery
atients because of its proximity, effectiveness, and low donor
orbidity rate. Reoperative groin surgery and patient-related
ound healing risk factors set the stage for cellulitis, break-
own, and possibly deep infection. This patient population
ill likely benefit the most frommuscle coverage especially in
rophylactic flaps Complicated Secondary flaps
68 98 42
13.3 14.2 16.1
$9403 $10,039 $11,383
217 $1246 $1246
0 $305 $305
$9620 $11,590 $12,934
$2409 $4379 $5723Phe setting of prosthetic reconstruction. We have shown that
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April 20121086 Fischer et alprophylactic muscle flaps are a reliable and effective interven-
tion that significantly reduce postoperative groin complica-
tions and the need for secondary muscle flaps.
Future studies must include a randomized trial evalu-
ating the effect of prophylactic muscle flaps in high-risk
patients and should be geared toward designing a simple
assessment tool to predict groin complication risk and
prophylactic groin flap benefit. A clear algorithm to assess
for appropriate, preoperative plastic surgery referral for
prophylactic flaps would also be beneficial.
CONCLUSIONS
Complications following open muscle surgery are com-
mon, costly, and lead to significant morbidity. Performing
prophylactic muscle flaps at the initial surgery in select high-
risk patients, like reoperative prosthetic bypasses, can signifi-
cantly reduce complications and morbidity. The SMF is an
ideal prophylactic flap in high-risk groin surgery patients be-
cause of its proximity, easy mobility, effectiveness, and low
complication rate. Prophylactic flaps should be considered in
patients at risk for wound breakdown undergoing high-risk
procedures. Based on the level III evidence provided in this
study, we advocate for the use of prophylactic muscle flaps in
high-risk groin surgery patients.
The authors thank Jeff Rohrbach, BSN, and the Division
of Finance for their assistance in cost analysis for this study.
AUTHOR CONTRIBUTIONS
Conception and design: JF, PF, EW, SK, GW
Analysis and interpretation: JF, JN, SK, LW, EW, GK
Data collection: JF, MN
Writing the article: JF
Critical revision of the article: JF, SK, MN, JN, LW, PF,
GW
Final approval of the article: JF, SK, JN, EW, GW
Statistical analysis: JF, JN
Obtained funding: Not applicable
Overall responsibility: JF, SK, EW
REFERENCES
1. Kent KC, Bartek S, Kuntz KM, Anninos E, Skillman JJ. Prospective
study of wound complications in continuous infrainguinal incisions
after lower limb arterial reconstruction: incidence, risk factors, and cost.
Surgery 1996;119:378-83.
2. Bandyk DF. Vascular surgical site infection: risk factors and preventive
measures. Semin Vasc Surg 2008;21:119-23.
3. Brothers TE, Robison JG, Elliott BM. Predictors of prosthetic graft
infection after infrainguinal bypass. J Am Coll Surg 2009;208:557-61.
4. Derksen WJ, Verhoeven BA, van de Mortel RH, Moll FL, de Vries JP.
Risk factors for surgical-site infection following common femoral artery
endarterectomy. Vasc Endovasc Surg 2009;43:69-75.
5. HatoumHT, Akhras KS, Lin SJ. The attributable clinical and economic
burden of skin and skin structure infections in hospitalized patients: a
matched cohort study. Diagn Microbiol Infect Dis 2009;64:305-10.
6. Antonios VS, Noel AA, Steckelberg JM, Wilson WR, Mandrekar JN,
Harmsen WS, et al. Prosthetic vascular graft infection: a risk factor
analysis using a case-control study. J Infect 2006;53:49-55.
7. Menzin J,Marton JP,Meyers JL, Carson RT, Rothermel CD, Friedman
M. Inpatient treatment patterns, outcomes, and costs of skin and skin
structure infections because of Staphylococcus aureus. Am J Infect
Contr 2010;38:44-9. S8. MoraschMD, Sam AD 2nd, KibbeMR,Hijjawi J, Dumanian GA. Early
results with use of gracilis muscle flap coverage of infected groin wounds
after vascular surgery. J Vasc Surg 2004;39:1277-83.
9. Illig KA, Alkon JE, Smith A, Rhodes JM, Keefer A, Doyle A, et al.
Rotational muscle flap closure for acute groin wound infections follow-
ing vascular surgery. Ann Vasc Surg 2004;18:661-8.
0. Daigeler A, Dodic T, Awiszus F, Schneider W, Fansa H. Donor-site
morbidity of the pedicled rectus femoris muscle flap. Plast Reconstr
Surg 2005;115:786-92.
1. Graham RG, Omotoso PO, Hudson DA. The effectiveness of muscle
flaps for the treatment of prosthetic graft sepsis. Plast Reconstr Surg
2002;109:108-13; Discussion:114-5.
2. Colwell AS, Donaldson MC, Belkin M, Orgill DP. Management of
early groin vascular bypass graft infections with sartorius and rectus
femoris flaps. Ann Plast Surg 2004;52:49-53.
3. ShermakMA, Yee K,Wong L, Jones CE,Wong J. Surgical management
of groin lymphatic complications after arterial bypass surgery. Plast
Reconstr Surg 2005;115:1954-62.
4. Calligaro KD, Veith FJ, Sales CM, Dougherty MJ, Savarese RP, De-
Laurentis DA. Comparison of muscle flaps and delayed secondary
intention wound healing for infected lower extremity arterial grafts.
Ann Vasc Surg 1994;8:31-7.
5. Evans GR, Francel TJ, Manson PN. Vascular prosthetic complications:
success of salvage with muscle-flap reconstruction. Plast Reconstr Surg
1993;91:1294-302.
6. Kimmel RM, Murphy RX, Chowdary RP. Optimal management of
inguinal vascular graft infections. Ann Plast Surg 1994;32:623-9.
7. Casey WJ, Jr, Rebecca AM, Krochmal DJ, Kim HY, Hemminger BJ,
Clarke HD, et al. Prophylactic flap reconstruction of the knee prior to
total knee arthroplasty in high-risk patients. Ann Plast Surg 2011;66:
381-7.
8. Chang DW, Friel MT, Youssef AA. Reconstructive strategies in soft
tissue reconstruction after resection of spinal neoplasms. Spine (Phila,
Pa 1976 2007 May 1;32:1101-6.
9. Armstrong PA, Back MR, Bandyk DF, Johnson BL, Shames ML.
Selective application of sartorius muscle flaps and aggressive staged
surgical debridement can influence long-term outcomes of complex
prosthetic graft infections. J Vasc Surg 2007;46:71-8.
0. Seify H, Moyer HR, Jones GE, Busquets A, Brown K, Salam A, et al.
The role of muscle flaps in wound salvage after vascular graft infections:
the Emory experience. Plast Reconstr Surg 2006;117:1325-33.
1. Landry GJ, Carlson JR, Liem TK, Mitchell EL, Edwards JM, Moneta
GL. The sartorius muscle flap: an important adjunct for complicated
femoral wounds involving vascular grafts. Am J Surg 2009;197:655-9;
Discussion:659.
2. Maser B, Vedder N, Rodriguez D, Johansen K. Sartorius myoplasty for
infected vascular grafts in the groin. Safe, durable, and effective. Arch
Surg 1997;132:522-5; Discussion:525-6.
3. Petrasek PF, Kalman PG, Martin RD. Sartorius myoplasty for deep
groin wounds following vascular reconstruction. Am J Surg 1990;160:
175-8.
4. SbitanyH, Koltz PF, Girotto JA, Vega SJ, LangsteinHN. Assessment of
donor-site morbidity following rectus femoris harvest for infrainguinal
reconstruction. Plast Reconstr Surg 2010;126:933-40.
5. Wu LC, Djohan RS, Liu TS, Chao AH, Lohman RF, Song DH.
Proximal vascular pedicle preservation for sartorius muscle flap transpo-
sition. Plast Reconstr Surg 2006;117:253-8.
6. CalderonW, Chang N,Mathes SJ. Comparison of the effect of bacterial
inoculation in musculocutaneous and fasciocutaneous flaps. Plast Re-
constr Surg 1986;77:785-94.
7. Chang N, Mathes SJ. Comparison of the effect of bacterial inoculation
in musculocutaneous and random-pattern flaps. Plast Reconstr Surg
1982;70:1-10.
8. Gosain A, Chang N, Mathes S, Hunt TK, Vasconez L. A study of the
relationship between blood flow and bacterial inoculation in musculo-
cutaneous and fasciocutaneous flaps. Plast Reconstr Surg 1990;86:
1152-62; Discussion:1163.ubmitted Sep 12, 2011; accepted Oct 19, 2011.
